Navigation Links
On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
Date:2/19/2008

ANN ARBOR, Mich., Feb. 19 /PRNewswire/ -- Compendia Bioscience, Inc. today announced results of a second productive year, including a renewed and expanding commitment from all major customers and the addition of several "Top 20" oncology drug companies to its customer roster. The new customers and existing customer commitment expansions led to a greater than 300% revenue increase, with similar growth forecasted for 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070213/NYTU093LOGO )

A key factor in Compendia's financial growth in 2007 was the mid-year release of Oncomine(TM) Concepts Edition, a unique analysis approach using drug and pathway signatures to help drug researchers and developers better understand a specific drug's biology and predict tumor populations likely to respond to the drug. Additionally, Compendia significantly expanded the Oncomine gene expression database in 2007 with cell line panels and drug perturbation studies, areas of specific interest for its customers.

"The addition of Oncomine Concepts Edition and targeted expansion of our data collection and curation efforts were key to our sales success last year, and multi-year commitments from customers have positioned us well for 2008 and beyond," said John Freshley, Compendia's Chief Business Officer. "We are particularly proud that we now count 12 of the top 20 oncology companies as our customers and are in active discussions with several more."

In addition, a major product milestone was completed in 2007 with the transition of the free academic offering from the University of Michigan to Compendia. With more than 15,000 user registrations, Oncomine has long been a leading tool for academic and non-profit researchers.

"This was a very significant step for Compendia," commented co-founder and CEO Dan Rhodes. "We have actively developed exciting new features for Oncomi
'/>"/>

SOURCE Compendia Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Spherix Reports Second Quarter Earnings
2. Tapestry Reports Second Quarter 2007 Results
3. Callisto Reports on Second-Quarter 2007 Milestones
4. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
11. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... /PRNewswire/ -- Asenapine -- an,investigational drug being developed ... Nobel, for bipolar I disorder and,schizophrenia -- was ... acute manic and mixed episodes associated with bipolar,I ... a study,presented at the American Psychiatric Association's 2007 ...
... Presented at 2007 APA Meeting -, COLLEGEVILLE, ... four new studies examining safety and efficacy ... studied as a potential treatment for adults,with ... at the,2007 American Psychiatric Association annual meeting ...
Cached Medicine Technology:Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8
(Date:4/24/2014)... Nancy Chiaravalloti, PhD, of Kessler Foundation was named ... Jersey City, New Jersey. Dr. Chiaravalloti spoke on April ... the topic of "Treating Cognitive Deficits Following Neurological Illness ... be a part of the long legacy of the ... Chiaravalloti. "The field of rehabilitation research is a rewarding ...
(Date:4/24/2014)... yeast is giving scientists a better understanding of drug ... illness world-wide. , When two or more medications ... or enhance the effectiveness of the other. Similarly, ... types of interactions are a major cause of illness ... on the practical scope of drug studies in humans. ...
(Date:4/24/2014)... ,Take me out to the ballgame, doesn,t exactly ... The more likely culprits include French fries, soda and ... children who play youth baseball, eating unhealthy food during ... according to researchers at Wake Forest Baptist Medical Center. ... Childhood Obesity , found that high-calorie snacks and ...
(Date:4/24/2014)... be boring and irrelevant, could offer an alternative to ... Dr Milena Furtado, and her team from the Australian ... heart cell fibroblast is a close relative to a ... , In research published today in Circulation Research ... unique cells due to their genetic program, and will ...
(Date:4/24/2014)... than to receive at least if you,re an adolescent ... study found that 15- and 16-year-olds who find pleasure in ... are less likely to become depressed than those who get ... for themselves. , The researchers detail their findings in the ... The study focused on the ventral striatum, a brain region ...
Breaking Medicine News(10 mins):Health News:Kessler Foundation scientist named 63rd Mendel Lecturer by St. Peter's University 2Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Take the bat, leave the candy 2Health News:Boring cells could hold the key to heart disease 2Health News:Study: Altruistic adolescents less likely to become depressed 2
... should,we die? Finding grace in life and death is an eternal ... Finding Grace on a Less Traveled Road is both an autobiography, ... a journey through the life of,a cancer physician who learns early, ... suffering. It is through the author,s own,understanding of what it means ...
... workers, sit-in shifted,national attention to the plight of laid-off workers, ... nightmarish loss of health,coverage benefits in layoffs and should know ... of Outten & Golden LLP. , ... the New York office of Outten &,Golden LLP which represents ...
... WEST PALM BEACH, Fla., Dec. 10 The Cosmetic ... for core cosmetic,physicians and their office staff will begin ... meeting has seen strong attendance and industry sponsorship.,According to ... the meeting,is recognized as the essential meeting for specialists ...
... New York and Wisconsin Among States with Hurdles Ahead, ... , NASHVILLE, Tenn., Dec. ... market intelligence, reports that states will face pressure to ... as commercially-insured members lose their jobs or come off ...
... Skilled Nursing Facilities , , ... 18-month selection process, a proven commitment to clinical quality ... (EMR) throughout Metropolitan Jewish Health System,s (Metropolitan) skilled nursing ... Metropolitan, a nationally recognized nonprofit organization, operates Metropolitan Jewish ...
... contracting portfolio, e-commerce exchange and clinical services , ... ... that Jordan Health Systems in Plymouth, Massachusetts has selected Broadlane as ... services to help manage its approximate $35 million in annual ...
Cached Medicine News:Health News:Finding Grace on a Less Traveled Road: A Cancer Doctor Reflects on Living and Dying 2Health News:Chicago Sit-In Highlights Laid-Off Workers, Employers' Obligations, and WARN Act, According to Outten & Golden LLP 2Health News:Chicago Sit-In Highlights Laid-Off Workers, Employers' Obligations, and WARN Act, According to Outten & Golden LLP 3Health News:Economic Downturn Means Increased Demands on Budget-Challenged State Health Coverage Initiatives 2Health News:Economic Downturn Means Increased Demands on Budget-Challenged State Health Coverage Initiatives 3Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 3Health News:Jordan Health Systems Selects Broadlane to Provide Comprehensive Supply Chain Services 2Health News:Jordan Health Systems Selects Broadlane to Provide Comprehensive Supply Chain Services 3
... Designed for precise punching of ... is designed for use with disposable ... block aids in centration of the ... the block is held centrally under ...
... Surgical Markers allows the surgeon ... with a scrub-resistant, gentian violet ... are provided sterile, with a ... in peel pouches. Micro tip ...
... Gentian violet ink ... prepping, Millimeter scale ruler ... barrel for quick measuring. ... with both inch and ...
Broad tip, gentian violet, sterile, disposable...
Medicine Products: